스텐트 시장 : 제품 유형, 재료, 전달 방법, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Stents Market is projected to grow by USD 25.33 billion at a CAGR of 7.75% by 2032.

The stents market is anchored by the global burden of cardiovascular, peripheral vascular, neurovascular, and urological disease. The World Health Organization identifies cardiovascular diseases as the leading cause of death worldwide, responsible for an estimated 17.9 million deaths annually, which sustains procedural demand for percutaneous coronary intervention, peripheral artery intervention, and other minimally invasive therapies.

Drug-eluting stents, covered stents, bare-metal stents, bioresorbable scaffolds, carotid stents, ureteral stents, and intracranial stent systems continue to evolve around three measurable priorities: improving vessel patency, reducing restenosis and thrombosis risk, and enabling faster patient recovery. Industry momentum is shaped by clinical guideline adoption, hospital catheterization laboratory capacity, reimbursement policy, material science, and stronger evidence requirements from regulators such as the U.S. FDA and European authorities under the Medical Device Regulation.

Transformative Shifts in the Stents Landscape

The stents landscape is shifting from device-centric competition toward evidence-led, procedure-integrated care. New-generation drug-eluting stents have largely displaced bare-metal stents in coronary intervention because randomized evidence and clinical guidelines support lower repeat revascularization rates in many patient groups. At the same time, peripheral vascular stents and covered stents are expanding with the rising diagnosis of peripheral artery disease, particularly among aging and diabetic populations.

Transformative change is also coming from imaging-guided intervention, radial access, complex lesion treatment, and device miniaturization. Intravascular ultrasound, optical coherence tomography, and fractional flow reserve are improving lesion assessment and stent optimization. Manufacturers are increasingly differentiating through polymer durability, drug-release profiles, alloy design, deliverability, radiopacity, and compatibility with complex anatomies rather than through platform claims alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the stents value chain from diagnosis to post-market surveillance. In clinical settings, AI-enabled image analysis can support coronary calcium assessment, lesion quantification, vessel sizing, and automated interpretation of angiography, CT angiography, intravascular ultrasound, and optical coherence tomography datasets. These capabilities are relevant because inappropriate sizing or incomplete lesion assessment can increase the risk of restenosis, malapposition, or repeat intervention.

AI is also strengthening manufacturing quality control, supply planning, inventory allocation, and adverse-event signal detection across regulated medical device ecosystems. However, adoption depends on validated algorithms, diverse training datasets, cybersecurity controls, explainability, and regulatory-grade evidence. Industry leaders that pair AI with prospective clinical validation and human-in-the-loop workflows are better positioned to improve procedural consistency without overstating autonomous decision-making.

Key Regional Insights for Stents

Asia-Pacific is a high-priority region for stents because of large patient pools, rising health insurance coverage, and expanding interventional cardiology capacity in China, India, Japan, South Korea, Australia, and Southeast Asia. The region is also influenced by the rapid increase in diabetes and hypertension, both recognized risk factors for coronary artery disease and peripheral artery disease. North America remains mature but innovation-intensive, supported by advanced catheterization laboratory infrastructure, FDA-cleared technologies, strong clinical trial activity, and high use of drug-eluting stents, covered stents, and peripheral vascular stents.

Latin America is advancing through public-private hospital investment and broader access to percutaneous coronary intervention in Brazil, Mexico, and major urban centers, though affordability, public reimbursement, and specialist distribution continue to shape access. Europe benefits from guideline-driven care, centralized procurement, established interventional cardiology networks, and MDR-led safety and post-market surveillance expectations. The Middle East is investing in tertiary cardiac centers, digital hospitals, and medical tourism hubs, while Africa presents long-term opportunity as cardiovascular diagnosis improves; however, access to interventional procedures remains uneven due to infrastructure gaps, specialist availability, and payer limitations.

Key Group Insights Across Major Economic Blocs

ASEAN demand is influenced by rising diabetes, hypertension, urbanization, and the buildout of cardiac care networks across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is characterized by high cardiovascular risk factors, significant public healthcare spending, and a preference for internationally validated technologies in leading hospitals. The European Union remains a benchmark for safety, traceability, clinical evidence, and post-market surveillance under the Medical Device Regulation, making regulatory readiness essential for coronary, peripheral, carotid, and ureteral stent suppliers.

BRICS countries combine large disease burdens with heterogeneous reimbursement, procurement, and domestic manufacturing systems, creating demand for both premium and cost-effective stent platforms. G7 markets drive clinical evidence generation, next-generation drug-eluting stent adoption, imaging-guided PCI, and long-term outcomes research. NATO countries are increasingly relevant to supply-chain resilience because medical device availability is viewed through healthcare security, logistics redundancy, sterile manufacturing continuity, and critical infrastructure preparedness.

Key Country Insights for Stents Demand

The United States leads in advanced coronary intervention, clinical trial activity, and FDA-regulated device innovation, while Canada emphasizes evidence-based reimbursement and equitable provincial access. Mexico and Brazil are important Latin American markets where urban cardiac centers support PCI adoption, although public-sector purchasing, reimbursement timing, and affordability shape the product mix. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from mature cardiology networks, national guideline alignment, and broad access to drug-eluting stents, with Germany maintaining a strong role in interventional procedure volume and medical technology adoption.

Russia presents demand for cardiovascular intervention but faces procurement and supply-chain complexity. China is scaling domestic stent manufacturing and expanding PCI access through hospital network development, while India is driven by a high coronary disease burden, price-sensitive procurement, and increasing access to interventional cardiology outside major metropolitan centers. Japan is distinguished by advanced imaging use, strict quality expectations, and strong procedural standardization. Australia and South Korea combine modern hospital infrastructure, reimbursement discipline, and high adoption of clinically validated stent technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation across real-world populations, including patients with diabetes, chronic kidney disease, calcified lesions, small vessels, bifurcation disease, and complex peripheral artery disease. Differentiation should focus on measurable outcomes such as target lesion failure, stent thrombosis, restenosis, deliverability, procedural efficiency, radial access compatibility, and long-term safety.

Organizations should also strengthen AI-enabled imaging partnerships, invest in resilient regional supply chains, and design market access strategies by reimbursement tier. In emerging markets, value-engineered platforms, physician training, clinical education, and financing partnerships can accelerate responsible adoption. In mature markets, clinical evidence, interoperability with imaging systems, post-market data transparency, and compliance with evolving medical device regulations will be decisive.

Research Methodology

This executive summary is developed from a structured secondary research methodology using verified public sources, including WHO disease burden data, regulatory guidance from the U.S. FDA and European medical device authorities, clinical guideline positions from major cardiology societies, peer-reviewed evidence on drug-eluting stents and PCI, and publicly available healthcare infrastructure indicators.

The analysis applies cross-validation across epidemiology, reimbursement, regulatory, clinical, and technology adoption signals. Interpretations avoid unsupported projections and emphasize observable drivers: disease prevalence, procedure access, device regulation, procurement behavior, clinical outcomes, physician adoption, and innovation readiness.

Conclusion

The stents market remains clinically essential as cardiovascular and vascular disease continue to pressure healthcare systems worldwide. Demand is being reshaped by drug-eluting platforms, covered stents, advanced imaging, AI-assisted decision support, and stronger regulatory expectations for safety and long-term evidence.

Sustainable growth will favor organizations that combine proven device performance with data transparency, physician training, supply reliability, and region-specific market access strategies. The next phase of competition will be defined not only by better stent design, but also by stronger integration into evidence-based, minimally invasive care pathways.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Stents Market, by Product Type

• 7.1. Coronary Stents
• 7.2. Gastrointestinal Stents
• 7.3. Neurovascular Stents
  • 7.3.1. Extracranial Carotid Artery Stents
  • 7.3.2. Intracranial Stents
• 7.4. Peripheral Stents
  • 7.4.1. Carotid Artery Stents
  • 7.4.2. Femoral Artery Stents
  • 7.4.3. Iliac Artery Stents
  • 7.4.4. Renal Artery Stents
• 7.5. Urological Stents
  • 7.5.1. Prostatic Stents
  • 7.5.2. Ureteral Stents

8. Stents Market, by Material

• 8.1. Metallic Stents
  • 8.1.1. Cobalt Chromium
  • 8.1.2. Nitinol
  • 8.1.3. Platinum Chromium
  • 8.1.4. Stainless Steel
• 8.2. Polymeric Stents
  • 8.2.1. Biodegradable Polymers
  • 8.2.2. Non-biodegradable Polymers

9. Stents Market, by Mode of Delivery

• 9.1. Balloon-Expandable Stents
• 9.2. Self-Expanding Stents

10. Stents Market, by Application

• 10.1. Cardiovascular Diseases
• 10.2. Gastrointestinal Obstructions
• 10.3. Neurovascular Conditions
• 10.4. Oncology-Related Applications
• 10.5. Peripheral Artery Disease (PAD)
• 10.6. Urological Disorders

11. Stents Market, by End User

• 11.1. Ambulatory Surgical Centers (ASCs)
• 11.2. Cardiology Centers
• 11.3. Hospitals
• 11.4. Specialty Clinics

12. Stents Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Stents Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Stents Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. B. Braun AG
• 16.3. Becton, Dickinson and Company
• 16.4. Biosensors International Group, Ltd.
• 16.5. Boston Scientific Corporation
• 16.6. Concept Medical
• 16.7. Cook Medical LLC
• 16.8. Cordis Corporation
• 16.9. Elixir Medical Corporation
• 16.10. ELLA - CS, s.r.o.
• 16.11. Endologix LLC
• 16.12. Glaukos Corporation
• 16.13. Hexacath
• 16.14. InspireMD, Inc.
• 16.15. Integer Holdings Corporation
• 16.16. Lepu Medical Technology Co., Ltd
• 16.17. Medinol Ltd.
• 16.18. Medtronic plc
• 16.19. Meril Life Sciences Pvt. Ltd
• 16.20. MicroPort Scientific Corporation
• 16.21. OrbusNeich Medical Group Holdings Limited
• 16.22. Relisys Medical Devices Limited
• 16.23. Sahajanand Medical Technologies Pvt. Ltd
• 16.24. Terumo Corporation
• 16.25. Translumina Therapeutics
• 16.26. W. L. Gore & Associates, Inc.